These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 26684693)

  • 21. Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation.
    Zhang Q; Deng YL; Liu C; Huang LH; Shang L; Chen XG; Wang LT; Du JZ; Wang Y; Wang PX; Zhang H; Shen ZY
    World J Gastroenterol; 2016 Nov; 22(43):9571-9585. PubMed ID: 27920478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Follow-up Imaging After Liver Transplantation Should Take Into Consideration Primary Hepatocellular Carcinoma Characteristics.
    Dioguardi Burgio M; Ronot M; Fuks D; Dondero F; Cauchy F; Gaujoux S; Dokmak S; Paradis V; Durand F; Belghiti J; Vilgrain V
    Transplantation; 2015 Aug; 99(8):1613-8. PubMed ID: 25710611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretransplant absolute monocyte count in peripheral blood predicts posttransplant tumor prognosis in patients undergoing liver transplantation for hepatocellular carcinoma.
    Kim YK; Kim SH; Lee SD; Lee SA; Park SJ
    Hepatobiliary Pancreat Dis Int; 2014 Jun; 13(3):250-8. PubMed ID: 24919607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
    An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.
    Takada Y; Kaido T; Shirabe K; Nagano H; Egawa H; Sugawara Y; Taketomi A; Takahara T; Wakabayashi G; Nakanishi C; Kawagishi N; Kenjo A; Gotoh M; Toyoki Y; Hakamada K; Ohtsuka M; Akamatsu N; Kokudo N; Takeda K; Endo I; Takamura H; Okajima H; Wada H; Kubo S; Kuramitsu K; Ku Y; Ishiyama K; Ohdan H; Ito E; Maehara Y; Honda M; Inomata Y; Furukawa H; Uemoto S; Yamaue H; Miyazaki M; Takada T;
    J Hepatobiliary Pancreat Sci; 2017 Jan; 24(1):49-57. PubMed ID: 27806426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation.
    Liu B; Teng F; Fu H; Guo WY; Shi XM; Ni ZJ; Gao XG; Ma J; Fu ZR; Ding GS
    BMC Gastroenterol; 2015 Oct; 15():138. PubMed ID: 26472203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peritransplant lymphopenia is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation.
    Nagai S; Abouljoud MS; Kazimi M; Brown KA; Moonka D; Yoshida A
    Transplantation; 2014 Mar; 97(6):694-701. PubMed ID: 24637868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
    Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?
    Fernandez-Sevilla E; Allard MA; Selten J; Golse N; Vibert E; Sa Cunha A; Cherqui D; Castaing D; Adam R
    Liver Transpl; 2017 Apr; 23(4):440-447. PubMed ID: 28187493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation.
    Teng F; Wang GH; Tao YF; Guo WY; Wang ZX; Ding GS; Shi XM; Fu ZR
    World J Gastroenterol; 2014 Aug; 20(31):10900-7. PubMed ID: 25152592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma.
    Zhu PP; Yuan SG; Liao Y; Qin LL; Liao WJ
    World J Gastroenterol; 2015 Jun; 21(23):7254-63. PubMed ID: 26109813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
    Mehta N; Heimbach J; Lee D; Dodge JL; Harnois D; Burns J; Sanchez W; Roberts JP; Yao FY
    Transplantation; 2017 Sep; 101(9):2071-2078. PubMed ID: 28353492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.